Previous work suggests a role for mast cell derived mediators in exercise induced asthma. The contribution of newly generated contractile prostaglandins to exercise induced asthma was assessed by using a potent and orally active thromboxane (TP,) receptor antagonist, GR32191. The effect of 120 mg GR32191 on exercise induced asthma was observed in 12 asthmatic subjects. For the exercise challenge the subjects performed six minutes of treadmill exercise, breathing dry air at a work load that had previously been shown to induce a fall in FEV, of 25% or more from the pre-exercise baseline. No effect of GR32191 on pre-exercise baseline airway calibre was evident. There was no significant difference in the mean maximum percentage fall in FEV, from baseline after exercise between drug and placebo (placebo 30-2%, GR32191 day 31-6%). It is concluded that the thromboxane antagonist GR32191 has no effect on exercise induced asthma. This suggests that prostaglandins, including PGD2, that act via the thromboxane receptor do not have an important role in exercise induced asthma.
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Exercise induced bronchoconstriction in asthma is believed to be due, at least in part, to ventilation over the six minutes of exercise on the two study days (215 (11) 1 on the placebo day v 220 (12)1 on the GR32191 day).
The maximum percentage fall in FEV, from the pre-exercise level after oral placebo was 30-2% (3-6%). Neither the maximum fall in FEV, nor the time course of bronchconstriction differed significantly between placebo and GR32 191 (figure and table). Neither a period effect nor a treatment-period interaction was evident. The study had a greater than 80% power of showing a 35% inhibition of the mean maximum percentage fall in FEVI.
Discussion
Using an antagonist of thromboxane TP, receptors, we have attempted for the first time to separate the component of bronchoconstriction in exercise induced asthma resulting from release of contractile prostaglandins. GR32191 failed to have any significant effect on the magnitude or time course of exercise induced asthma. These data do not support a role for contractile prostaglandins, including mast cell derived PGD2, in exercise induced asthma.
Using human bronchial muscle preparations, Coleman and Sheldrick'0 have shown that U-46619, a stable thromboxane mimetic, is the most potent prostanoid contractile agonist, being 383 fold and 628 fold more potent on a molar basis than PGF2, and PGD2. As the competitive antagonist AH23848 displaced the dose-response curves for all these prostaglandins to a similar degree they suggested that the prostaglandins mediate their bronchoconstrictor effect via the same receptor, the thromboxane prostaglandin receptor (TPI). '4 Armour et all'5 found that GR32191, an analogue of AH23848, potently inhibited contractions induced by PGF25 and U-46619 in human bronchial rings, and also protected against the contractile but not the relaxant effect of PGE2. Featherstone et al'6 found GR32191
to be a potent antagonist in vitro of human airway smooth muscle contraction by PGD2, PGF20, PGF9,5, PGF951,,-PGF2, and U466191.
GR32191 was the most potent of the thromboxane antagonists we studied, and was as potent in protecting against PGD2 induced contraction as against U466191 induced contraction, with an estimated two fold shift to the right of the dose-response curve at a concentration of the antagonist in the nanomolar range.
No effect on methacholine induced contraction was observed at the highest concentration of GR32191 given. The specificity ofGR32191 in vitro has been confirmed by other investigators; it does not protect against bronchial muscle contraction induced by carbachol,'5 histamine, presumably by filling bronchial vessels. Four of our subjects were taking inhaled corticosteroids (table) , and we might argue, despite the discontinuation of these drugs 12 hours before challenge, that this had inhibited the contribution of cyclo-oxygenase products to exercise induced asthma in these subjects. Although this is possible for prostanoids from non-mast cell sources, the production of PGD2 from mast cells is unaffected in vitro by corticosteroids. 22 We have shown that GR32191 fails to inhibit bronchoconstriction induced by exercise in asthmatic subjects. Our findings do not support a role for contractile prostanoids acting through the TP, receptor in the genesis of exercise induced bronchoconstriction.
